Prader-Willi Syndrome Market Epidemiology Report, Size, Share, Trends and Forecast 2025-2035

According to the IMARC Group, the Prader-Willi syndrome market size reached a value of USD 639.9 million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,302.9 million by 2035, exhibiting a growth rate (CAGR) of 6.68% during 2025-2035. This can be attributed to the emerging popularity of intranasal selective oxytocin receptors, since they can aid in appetite regulation and improve social functioning, reduce repetitive behaviors, as well as address hyperphagia in patients.

Prader-Willi syndrome represents a rare genetic disorder that occurs due to the loss of specific genes on chromosome 15, which are usually inherited from the father. The Prader-Willi syndrome market is experiencing notable growth due to the rising awareness about genetic disorders among healthcare professionals and the public, which is fostering early diagnosis and intervention, significantly enhancing patient outcomes. Besides this, advancements in genetic testing technologies, such as chromosomal microarray analysis and next-generation sequencing, are facilitating accurate identification of the disorder, increasing the demand for diagnostic solutions, further augmenting the Prader-Willi syndrome market expansion.

The development of novel therapeutic approaches, including growth hormone therapy, which addresses key symptoms like short stature and body composition, is driving treatment adoption. Additionally, the growing focus on targeted therapies for hyperphagia, a hallmark symptom of the condition, is also fueling the Prader-Willi syndrome market growth, with several promising candidates under development. Increasing investment in research and development activities by pharmaceutical companies and academic institutions is leading to a pipeline of innovative treatments designed to manage the complex manifestations of the disorder. Moreover, favorable regulatory incentives, such as orphan drug designations and funding for rare disease research, encouraging industry participation, are also stimulating the Prader-Willi syndrome market expansion. Furthermore, the use of digital health platforms for remote monitoring and management of the illness, ensuring continuity of care and enhancing patient engagement, is anticipated to propel the Prader-Willi syndrome market growth over the forecasted period.

Request for a sample of this report: https://www.imarcgroup.com/prader-willi-syndrome-market/requestsample

Key Highlights:

• The prevalence of Prader-Willi syndrome is one in every 20,000 to 30,000 births.
• Prader-Willi syndrome affects around 400,000 people worldwide, 20,000 of whom live in the United States.
• It remains the most common hereditary cause of life-threatening obesity.
• The reported prevalence rates for Prader-Willi syndrome range from one per 8,000 people in rural Sweden to one per 16,000 people in western Japan.
• The annual mortality rate of PWS ranges between 1% and 4%.

This report also provides a detailed analysis of the current Prader-Willi syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Competitive Landscape with key players:

The competitive landscape of the Prader-Willi syndrome market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Pfizer
2. Sandoz
3. Soleno Therapeutics
4. Harmony Biosciences
5. Acadia Pharmaceuticals
6. ConSynance Therapeutics
7. Aardvark Therapeutics

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hyperuricemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hhyperuricemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145